Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 2022-2028

  Konig, Maximilian F ^a   Giles, Jon T ^b   Nigrovic, Peter A ^c,d   Andrade, Felipe ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Ant CCP; Autoantibodies; Rheumatoid Arthritis

Indexed keywords

AUTOANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN GROUP A B; HNRNP A2;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELL CLONING; CELL LYSATE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ARTHRITIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIAL FLUID; ADULT; BLOOD; CASE CONTROL STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; METABOLISM; PATHOLOGY;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; CITRULLINE; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNE TOLERANCE; LONGITUDINAL STUDIES; MALE; PEPTIDES, CYCLIC; SYNOVIAL FLUID;

EID: 84959099710     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208529     Document Type: Article

References (40)

1. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
2. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:593-601.
3. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
5. Edelman GM, Kunkel HG, Franklin EC. Interaction of the rheumatoid factor with antigen-Antibody complexes and aggregated gamma globulin. J Exp Med 1958;108:105-20.
6. Steiner G, Hartmuth K, Skriner K, et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 1992;90:1061-6.
7. Mimori T, Suganuma K, Tanami Y, et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995;92:7267-71.
8. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
9. Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008;58:1958-67.
10. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
11. Nell-Duxneuner V, Machold K, Stamm T, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: A follow-up study. Ann Rheum Dis 2010;69:169-74.
12. Darrah E, Giles JT, Ols ML, et al. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 2013;5:186ra65.
13. Giles JT, Darrah E, Danoff S, et al. Association of cross-reactive antibodies targeting peptidyl-Arginine deiminase 3 and 4 with rheumatoid arthritis-Associated interstitial lung disease. PLoS ONE 2014;9:e98794.
14. van Steenbergen HW, Ajeganova S, Forslind K, et al. The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis. Ann Rheum Dis 2015;74:e3.
15. Shelef MA, Sokolove J, Lahey LJ, et al. Peptidylarginine deiminase 4 contributes to tumor necrosis factor alpha-induced inflammatory arthritis. Arthritis Rheumatol 2014;66:1482-91.
16. Hayer S, Tohidast-Akrad M, Haralambous S, et al. Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-Associated anti-RA33 autoantibodies in TNF-Alpha transgenic mice. J Immunol 2005;175:8327-36.
17. Hoffmann MH, Tuncel J, Skriner K, et al. The rheumatoid arthritis-Associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol 2007;179:7568-76.
18. Konig MF, Darrah E, Andrade F. Insights into the significance of peptidylarginine deiminase 4 and antibodies against citrullinated antigens in the absence of "true ACPAs" in an experimental model of arthritis: comment on the article by Shelef et al. Arthritis Rheumatol 2014;66:2642-4.
19. Stoop JN, Fischer A, Hayer S, et al. Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. Ann Rheum Dis 2015;74:949-50.
20. Shelef MA, Sokolove J, Robinson WH, et al. Reply: To PMID 24497204. Arthritis Rheumatol 2014;66:2644-5.
21. Giles JT, Szklo M, Post W, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 2009;11:R36.
22. Konig MF, Paracha AS, Moni M, et al. Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. Ann Rheum Dis 2015;74:2054-61.
23. Hassfeld W, Steiner G, Hartmuth K, et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989;32:1515-20.
24. Op De Beéck K, Maes L, Van den Bergh K, et al. Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases. Arthritis Rheum 2012;64:213-21.
25. Maslyanskiy A, Lazareva N, Olinek P, et al. Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis. J Immunol Res 2014;2014:516593.
26. Tutturen AE, Fleckenstein B, de Souza GA. Assessing the citrullinome in rheumatoid arthritis synovial fluid with and without enrichment of citrullinated peptides. J Proteome Res 2014;13:2867-73.
27. Herman S, Fischer A, Presumey J, et al. Inhibition of Inflammation and Bone Erosion by RNA Interference-Mediated Silencing of Heterogeneous Nuclear RNP A2/B1 in Two Experimental Models of Rheumatoid Arthritis. Arthritis Rheumatol 2015;67:2536-46.
28. Han SP, Friend LR, Carson JH, et al. Differential subcellular distributions and trafficking functions of hnRNP A2/B1 spliceoforms. Traffic 2010;11:886-98.
29. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1196-201.
30. Després N, Boire G, Lopez-Longo FJ, et al. The Sa system: A novel antigen-Antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-33.
31. Terato K, Shimozuru Y, Katayama K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990;33:1493-500.
32. Shrivastav M, Mittal B, Aggarwal A, et al. Autoantibodies against cytoskeletal proteins in rheumatoid arthritis. Clin Rheumatol 2002;21:505-10.
33. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011;108:17372-7.
34. Darrah E, Andrade F. Editorial: citrullination, and carbamylation, and malondialdehyde-Acetaldehyde! Oh my! Entering the forest of autoantigen modifications in rheumatoid arthritis. Arthritis Rheumatol 2015;67:604-8.
35. Brink M, Hansson M, Rönnelid J, et al. The autoantibody repertoire in periodontitis: A role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinated peptides. Ann Rheum Dis 2014;73: e46.
36. de Pablo P, Dietrich T, Chapple IL, et al. The autoantibody repertoire in periodontitis: A role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Ann Rheum Dis 2014;73:580-6.
37. Quirke AM, Perry E, Cartwright A, et al. Bronchiectasis is a Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis. Arthritis Rheumatol 2015;67:2335-42.
38. Romero V, Fert-Bober J, Nigrovic PA, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med 2013;5:209ra150.
39. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7: e35296.
40. Wagner CA, Sokolove J, Lahey LJ, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: Association with cigarette smoking and HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2015;74:579-86.